INTRODUCTION {#s1}
============

Retinal vein occlusion (RVO) is a multifactorial vascular disease characterized by retinal blood stasis, venous tortuous expansion, retinal hemorrhage, and edema that can cause loss of visual acuity loss or blindness \[[@R1]\]. There are two main types of RVO, branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO), which are classified according to the sites of occlusion \[[@R2], [@R3]\]. Systemic vascular disorders including hypertension, arteriosclerosis, and diabetes mellitus, as well as genetic background and environmental factors have been associated with the risk of RVO \[[@R4], [@R5]\]. Single nucleotide polymorphisms (SNPs) in several hemostasis-associated genes such as *Factor V*, *Prothrombin* (*Factor II*), and *PAI-1*, may contribute to the pathogenesis of RVO \[[@R4], [@R6]\].

Factor V, a co-factor in the prothrombinase complex, has an essential role in blood coagulation, and modulates the conversion of prothrombin to thrombin \[[@R7]\]. *Factor V* G1691A (*Factor V* Leiden or R506Q), is a frequently observed mutation in *Factor V* that has been associated with activated protein C (APC) resistance and several diseases including Budd-Chiari syndrome, portal vein thrombosis, and RVO \[[@R8]--[@R10]\]. The most recent meta-analysis of genetic variants associated with RVO was published in 2013 and involved 21 case-control studies \[[@R11]\]. Therefore, we performed an updated meta-analysis of 37 case-control studies under all genetic models.

RESULTS {#s2}
=======

Identification of eligible case-control studies {#s2_1}
-----------------------------------------------

A flow diagram showing the process by which we identified eligible case-control studies is shown in Figure [1](#F1){ref-type="fig"}. We initially found 498 articles in the PubMed (*n* = 102), Embase (*n* = 111), and Web of Science (WOS, *n* = 285) databases. We removed 120 duplicate articles, and excluded 179 articles (69 review articles or editorials, 63 case or trial reports, 43 meeting abstract or posters, and four meta-analyses). We also excluded 22 articles that were based on cell or animal data, and 134 articles that involved unrelated diseases, genes, or SNPs. Of the remaining 43 articles, three were excluded due to genotype departure from Hardy-Weinberg equilibrium (HWE) and three due to a lack of available genotype data. We included 37 articles that contained 2, 510 cases and 3,466 controls \[[@R6], [@R11]--[@R46]\] in our meta-analysis. Basic study information is shown in Table [1](#T1){ref-type="table"}. All studies had Newcastle-Ottawa Scale (NOS) scores above five.

![PRISMA 2009 flow diagram showing the process for identifying eligible case-control studies](oncotarget-08-75467-g001){#F1}

###### Basic information for the studies included in the meta-analysis

  First author       Year   Country       Ethnicity   Cases   Disease type   Controls   Assay   Source   NOS                                                            
  ------------------ ------ ------------- ----------- ------- -------------- ---------- ------- -------- ----- ------ ---- ----- ------------------------------ ------- ---
  Adamczuk           2002   Argentina     Caucasian   37      0              0          37      CRVO     140   4      0    144   PCR-RFLP                       PB      8
  Albisinni          1998   Italy         Caucasian   32      4\*            \-         36      RVO      67    1\*    \-   68    PCR-RFLP                       HB      7
  Arsene             2005   France        Caucasian   143     10             0          153     CRVO     172   8      0    180   PCR-RFLP                       PB/HB   6
                                          Caucasian   79      2              0          81      BRVO     172   8      0    180   PCR-RFLP                       PB/HB   
  Batioglu           2003   Turkey        Caucasian   8       7\*            \-         15      RVO      257   28\*   \-   285   PCR-RFLP                       PB      7
                                          Caucasian   6       9\*            \-         15      BRVO     257   28\*   \-   285   PCR-RFLP                       PB      
  Biancardi          2007   Brazil        Caucasian   53      2              0          55      RVO      55    0      0    55    PCR-RFLP                       HB      6
  Bombeli            2002   Switzerland   Caucasian   65      3\*            \-         68      RVO      112   8\*    \-   120   PCR-RFLP                       PB      7
  Ciardella          1998   USA           Caucasian   29      1              0          30      RVO      46    1      0    47    PCR-RFLP                       HB      7
  Cruciani           2003   Italy         Caucasian   29      0              0          29      RVO      61    1      0    62    PCR-RFLP                       PB      7
  De Polo            2015   Italy         Caucasian   32      5              0          37      RVO      43    2      0    45    PCR-RFLP                       PB      7
  Delahousse         1998   France        Caucasian   76      7              0          83      RVO      60    0      0    60    PCR-RFLP                       PB      6
  Demirci            1999   Turkey        Caucasian   20      3              0          23      CRVO     109   11     0    120   PCR-RFLP                       PB      7
                                          Caucasian   24      1              0          25      BRVO     109   11     0    120   PCR-RFLP                       PB      
  Di Capua           2010   Italy         Caucasian   109     8              0          117     RVO      191   11     0    202   PCR-RFLP                       PB      9
  Dixon              2016   USA           Caucasian   52      8              0          60      RVO      60    2      0    62    PCR                            PB      7
  Dodson             2003   UK            Caucasian   39      1              0          40      RVO      39    1      0    40    PCR-RFLP                       PB      9
  Faude              1999   Germany       Caucasian   101     6              0          107     CRVO     66    4      0    70    PCR-RFLP                       PB      6
  Giannaki           2013   Greece        Caucasian   47      4              0          51      RVO      46    5      0    51    CVD Strip Assay                PB      8
  Glueck             1999   USA           Caucasian   14      3              0          17      RVO      226   7      0    233   PCR-RFLP                       PB      8
  Glueck             2005   USA           Caucasian   20      3              0          23      RVO      43    1      0    44    PCR                            PB      7
  Gori               2004   Italy         Caucasian   99      13             0          112     RVO      107   5      0    112   PCR-RFLP                       PB      9
  Graham             1996   Australia     Caucasian   22      1              0          23      CRVO     109   4      0    113   PCR-RFLP                       PB      7
  Greiner            1999   Germany       Caucasian   35      12             1          48      CRVO     32    3      0    35    PCR                            HB      5
                                          Caucasian   27      6              0          33      BRVO     32    3      0    35    PCR                            HB      
  Horoz              2005   Turkey        Caucasian   29      2              1          32      BRVO     27    3      0    30    NR                             PB      8
  Johnson            2001   Canada        Caucasian   43      1              0          44      CRVO     68    3      0    71    PCR-RFLP                       HB      6
  Kalayci            1999   Turkey        Caucasian   48      4              0          52      RVO      75    6      0    81    PCR-RFLP                       PB      7
                                          Caucasian   24      3              0          27      BRVO     75    6      0    81    PCR-RFLP                       PB      
  Karska-Basta       2013   Poland        Caucasian   53      6              0          59      RVO      50    9      0    59    PCR                            PB      8
  Koylu              2017   Turkey        Caucasian   43      3              3          49      RVO      64    4      0    68    PCR-RFLP                       PB      7
  Kuhli              2002   Germany       Caucasian   129     11             2          142     RVO      122   6      0    128   PCR-RFLP                       PB      7
  Kuhli-Hattenbach   2017   Germany       Caucasian   34      8              0          42      RVO      230   11     0    241   PCR-RFLP                       PB      7
  Lahey              2002   USA           Mixed       53      2              0          55      CRVO     21    0      0    21    Coatest APC Resistance V Kit   PB      7
  Larsson            1997   Sweden        Caucasian   74      8              1          83      CRVO     90    10     1    101   PCR-RFLP                       PB      6
  Marcucci           2001   Italy         Caucasian   88      12             0          100     CRVO     96    4      0    100   PCR-RFLP                       PB      7
  Marcucci           2003   Italy         Caucasian   47      8\*            \-         55      RVO      59    2\*    \-   61    PCR-RFLP                       PB      8
  Mrad               2014   Tunisie       African     46      42             0          88      RVO      94    5      0    99    PCR-RFLP                       PB      8
  Rehak              2010   Czech         Caucasian   74      5\*            \-         79      CRVO     56    4\*    \-   60    Allele-specific PCR            HB      7
                                          Caucasian   36      6\*            \-         42      BRVO     56    4\*    \-   60    Allele-specific PCR            HB      
  Risse              2014   Germany       Caucasian   83      3              0          86      CRVO     39    1      0    40    PCR                            PB      7
                                          Caucasian   45      2              0          47      BRVO     39    1      0    40    PCR                            PB      
  Salomon            1998   Israel        Asian       95      7\*            \-         102     RVO      96    9\*    \-   105   PCR-RFLP                       HB      6
  Yioti              2013   Greece        Caucasian   47      1              0          48      RVO      53    0      0    53    CVD Strip Assays               HB      6

RFLP, restriction fragment-length polymorphism; CVD, Cardiovascular disease panel; \*, the frequency of the G/A+A/A genotype.

Overall meta-analysis {#s2_2}
---------------------

We analyzed the association between *Factor V* G1691A and RVO susceptibility using a fixed-effects model and Mantel-Haenszel statistics. We did not observe a high degree of heterogeneity between the various models (AA vs. GG, AA vs. GG+GA, A vs. G (carrier) \[all I^2^ \< 50%, *P* value of the heterogeneity test (*P*~H~) \> 0.1\] (Table [2](#T2){ref-type="table"}). An increased risk of RVO in cases compared to controls was observed under allele, heterozygote, dominant, and carrier models (G vs. A, *P* value of the association test \[*P*~A~\] \< 0.001, odds ratio \[OR\] = 1.98; GA vs. GG, *P*~A~ \< 0.001, OR = 1.90; GA+AA vs. GG, *P*~A~ \< 0.001, OR = 2.01; A vs. G carrier, *P*~A~ \< 0.001, OR = 1.96), but not homozygote and recessive models (all *P*~A~ \> 0.05). Forest plots are shown for the meta-analysis under A vs. G (allele) (Figure [2](#F2){ref-type="fig"}), GA+AA vs. GG (Figure [3](#F3){ref-type="fig"}), AA vs. GG ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}), GA vs. GG ([Supplementary Figure 2](#SD1){ref-type="supplementary-material"}), AA vs. GG+GA ([Supplementary Figure 3](#SD1){ref-type="supplementary-material"}), and A vs. G (carrier) ([Supplementary Figure 4](#SD1){ref-type="supplementary-material"}) models. These data indicate that the G/A genotype of *Factor V* G1691A is associated with an increased risk of RVO.

###### Meta-analysis of the association between Factor V G1691A and RVO

  Genetic models          Case-control study number   Sample size   Association test    Heterogeneity test           Begg's test   Egger's test                           
  ----------------------- --------------------------- ------------- ------------------- -------------------- ------- ------------- -------------- ------- ------- ------- -------
  **A vs. G (allele)**    31                          2,113/2,767   1.98 (1.45∼2.72)    **\< 0.001**         32.1%   0.046         Random         0.54    0.587   −0.13   0.897
  **AA vs. GG**           5                           387/362       3.38 (0.93∼12.35)   0.065                0.0%    0.855         Fixed          -0.24   1.000   0.22    0.843
  **GA vs. GG**           31                          2,113/2,767   1.90 (1.34∼2.70)    **\< 0.001**         39.8%   0.013         Random         0.68    0.497   −0.28   0.784
  **GA+AA vs. GG**        37                          2,510/3,466   2.01 (1.46∼2.78)    **\< 0.001**         43.7%   0.003         Random         0.67    0.505   0.08    0.937
  **AA vs. GG+GA**        5                           387/362       3.30 (0.90∼12.04)   0.071                0.0%    0.843         Fixed          -0.24   1.000   0.16    0.882
  **A vs. G (carrier)**   31                          2,113/2,767   1.96 (1.55∼2.48)    **\< 0.001**         18.0%   0.189         Fixed          0.61    0.541   −0.09   0.928

*P*~B~, *P* value of Begg's test; *P*~E~, *P* value of Egger's test.

![Forest plot data for the meta-analysis under the A vs. G (allele) model](oncotarget-08-75467-g002){#F2}

![Forest plot data for the meta-analysis under the GA+AA vs. GG model](oncotarget-08-75467-g003){#F3}

Subgroup meta-analysis {#s2_3}
----------------------

We next performed a subgroup analysis based on ethnicity, source of controls (population-based \[PB\] or hospital-based \[HB\]), and disease type (BRVO/CRVO) under all genetic models. *Factor V* G1691A was associated with an increased risk of RVO compared to controls in a Caucasian population under A vs. G (allele) (Table [3](#T3){ref-type="table"}, *P*~A~ \< 0.001, OR = 1.75), GA vs. GG (*P*~A~ \< 0.001, OR = 1.66), GA+AA vs. GG (*P*~A~ \< 0.001, OR = 1.88), and A vs. G (carrier) (*P*~A~ \< 0.001, OR = 1.66) models. *Factor V* G1691A was also associated with an increased risk of RVO among cases compared to PB controls. Eight BRVO and 13 CRVO studies were included in the disease subgroup meta-analysis. We observed an increased risk of CRVO, but not BRVO, under allele, heterozygote, dominant, and carrier models. Forest plots for the subgroup analysis under the A vs. G (allele) and GA+AA vs. GG models are shown in [Supplementary Figures 5](#SD1){ref-type="supplementary-material"}--[6](#SD1){ref-type="supplementary-material"}. Our data indicate G/A genotype of *Factor V* G1691A is associated with an increased risk of RVO (particularly CRVO) in Caucasians.

###### Subgroup analysis of the association between Factor V G1691A and RVO

  Genetic model           Subgroup    Case-control study number   Association test    Sample size    Heterogeneity test           
  ----------------------- ----------- --------------------------- ------------------- -------------- -------------------- ------- -------
  **A vs. G (allele)**    Caucasian   29                          1.75 (1.35∼2.28)    **\< 0.001**   1,970/2,647          4.0%    0.405
                          BRVO        6                           1.11 (0.59∼2.08)    0.750          245/486              0.0%    0.719
                          CRVO        12                          1.66 (1.14∼2.42)    **0.008**      840/1,030            0.0%    0.744
                          PB          25                          2.03 (1.41∼2.92)    **\< 0.001**   1,621/2,326          40.6%   0.019
                          HB          5                           2.29 (0.91∼5.77)    0.080          258/261              0.0%    0.697
  **AA vs. GG**           Caucasian   5                           3.38 (0.93∼12.35)   0.065          287/362              0.0%    0.855
                          CRVO        3                           1.70 (0.30∼9.73)    0.548          212/171              0.0%    0.931
                          PB          4                           3.90 (0.95∼16.06)   0.060          306/327              0.0%    0.768
  **GA vs. GG**           Caucasian   29                          1.66 (2.16∼1.28)    **\< 0.001**   1,970/2,647          5.5%    0.381
                          BRVO        6                           1.01 (0.52∼1.95)    0.987          245/486              0.0%    0.643
                          CRVO        12                          1.65 (1.12∼2.44)    **0.012**      840/1,030            0.0%    0.780
                          PB          25                          1.93 (1.28∼2.90)    **0.002**      1,621/2,326          48.2%   0.004
                          HB          5                           2.25 (0.87∼5.79)    0.093          258/261              0.0%    0.703
  **GA+AA vs. GG**        Caucasian   34                          1.88 (1.42∼2.50)    **\< 0.001**   2,265/3,241          22.0%   0.128
                          BRVO        8                           1.89 (1.15∼3.11)    **0.011**      302/831              60.6%   0.013
                          CRVO        13                          1.60 (1.11∼2.33)    **0.013**      919/1.090            0.0%    0.761
                          PB          28                          2.13 (1.45∼3.13)    **\< 0.001**   1,759/2,792          50.6%   0.001
                          HB          8                           1.59 (0.89∼2.84)    0.117          517/494              0.0%    0.440
  **AA vs. GG+GA**        Caucasian   5                           3.39 (0.90∼12.04)   0.071          287/362              0.0%    0.843
                          CRVO        3                           1.52 (0.26∼8.74)    0.639          212/171              0.0%    0.958
                          PB          4                           3.89 (0.94∼16.03)   0.060          306/327              0.0%    0.773
  **A vs. G (carrier)**   Caucasian   29                          1.66 (1.29∼2.14)    **\< 0.001**   1,970/2,647          0.0%    0.632
                          BRVO        6                           1.05 (0.54∼2.01)    0.892          245/486              0.0%    0.764
                          CRVO        12                          1.58 (1.07∼2.33)    **0.020**      840/1,030            0.0%    0.860
                          PB          25                          2.03 (1.57∼2.61)    **\< 0.001**   1,621/2,326          28.3%   0.095
                          HB          5                           2.16 (0.90∼5.20)    0.085          258/261              0.0%    0.743

Publication bias and sensitivity analysis {#s2_4}
-----------------------------------------

Our analysis indicated there was no publication bias (Table [2](#T2){ref-type="table"}, all *P*~Begg~ \> 0.05 and *P*~Egger~ \> 0.05). Begg's funnel plots with pseudo 95% confidence limits under the A vs. G (allele) and GA+AA vs. GG models are shown in Figure [4](#F4){ref-type="fig"}. Sensitivity analysis (Figure [5](#F5){ref-type="fig"} for the GA+AA vs. GG model and data not shown) was indicative of stable statistical results.

![Begg's funnel plot data with pseudo 95% confidence limits\
(**A**) A vs. G (allele); (**B**) GA+AA vs. GG.](oncotarget-08-75467-g004){#F4}

![Sensitivity analysis data under the GA+AA vs. GG model](oncotarget-08-75467-g005){#F5}

DISCUSSION {#s3}
==========

The G/A genotype of *Factor V* G1691A was previously associated with an increased risk of RVO in French \[[@R14]\] and Tunisian \[[@R43]\] populations. However, no differences in the frequency of the *Factor V* G1691A polymorphism between RVO cases and controls were reported in studies of Turkish populations \[[@R22], [@R32], [@R36]\]. Janssen et al. performed a meta-analysis of 12 studies \[[@R12], [@R13], [@R17], [@R22], [@R27], [@R33], [@R34], [@R39], [@R41], [@R42], [@R46], [@R47]\] and found that the *Factor V* Leiden mutation (G/A+A/A) was associated with an increased risk of RVO \[[@R48]\]. Rehak et al. performed a meta-analysis of 18 studies \[[@R13], [@R14], [@R17], [@R19], [@R22], [@R29], [@R31], [@R34], [@R37], [@R40]--[@R42], [@R47], [@R49]--[@R53]\] and reported similar results \[[@R52]\]. Finally, Yioti et al. performed a meta-analysis of 21 case-control studies \[[@R11]--[@R14], [@R16]--[@R19], [@R21]--[@R23], [@R28], [@R29], [@R33], [@R34], [@R37], [@R41], [@R42], [@R51], [@R53], [@R54]\] and demonstrated that the *Factor V* Leiden mutation was associated with an increased risk of RVO \[[@R11]\].

The A/A genotype of *Factor V* was previously observed in several studies \[[@R31], [@R32], [@R36], [@R37], [@R40]\]. However, only the contribution of G/A+A/A genotype of *Factor V* G1691A to RVO was described; the roles of the individual G/A or A/A genotypes were not investigated. Several factors including ethnic background, source of controls (PB/HB), and disease type (BRVO/CRVO) were also not sufficiently analyzed in previous studies \[[@R11], [@R48], [@R52]\]. Therefore, we performed a meta-analysis of 37 case-control studies, under allele (A vs. G), homozygote (AA vs. GG), heterozygote (GA vs. GG), dominant (GA+AA vs. GG), recessive (AA vs. GG+GA), and carrier (A vs. G) models. Our data indicate that the presence of a single *Factor V* Leiden allele increases the risk of RVO. The G/A genotype of *Factor V*, but not the A/A genotype, was an inherited risk factor for RVO in a Caucasian population. Moreover, when we stratified by type of RVO, heterozygosity was associated with an increased risk of CRVO, but not BRVO. The mechanisms underlying the association between *Factor V* G1691A and RVO have not been elucidated. It is possible that *Factor V* mutations lead to resistance to anticoagulant processing, and activated APC resistance or protein S deficiency may be the key points, which are worthy of future experiment data.

Our study had several advantages. First, we performed a quantitative analysis of a large number of case-control studies selected from three independent databases. Second, we excluded studies involving genotype data that deviated from Hardy-Weinberg Equilibrium, which confirmed the balance of gene frequency and genotype frequency, and enabled rigorous statistical analysis. Third, under the guideline of our strict inclusion and exclusion criteria, the enrolled case-control studies exhibit the high publication quality. Among them, we found that population-based control data is involved in most of studies. The data from the comparison between RVO case and healthy control subjects from the normal population is more helpful to drive a more reasonable statistical assessment for the genetic role of *Factor V* Leiden allele in the clinical RVO cases. We also performed subgroup analyses according to ethnicity (Caucasian/Asian), source of controls (PB/HB), and disease type (BRVO/CRVO). Finally, we detected no publication bias and demonstrated stable statistical results in a sensitivity analysis.

Our study also had several disadvantages. First, the sample size of the included case-control studies was relatively small, which limited the statistical power in the subgroup meta-analysis. For example, only one case-control study was enrolled in the subgroup analysis for the association between *Factor V* G1691A and susceptibility to RVO in an Asian population \[[@R46]\]. Second, although there was no clear association between the A/A genotype of *Factor V* G1691A and the risk of RVO, we cannot exclude the potential genetic effect of homozygosity. The low prevalence of the A/A genotype may have contributed to the underpowered meta-analysis. Third, only the G1691A SNP was investigated in our study due to data availability. We did not analyze the role of other SNPs (e.g. G4070A), or the combination of *Factor V* and other relative genes such as *MTHFR* and *prothrombin*. Fourth, the main clinical types of retinal vein occlusion, namely BRVO and CRVO, and other uncommon types, such as bilateral RVO, exhibit the differences or complexity of physiopathology \[[@R1]--[@R3], [@R55]\]. Unfortunately, we failed to obtain the SNP data of the association between *Factor V* Leiden and bilateral RVO risk. Confounding factors such as sex, age of onset, family history, lifestyle, clinical type, and complications should be investigated in future meta-analyses of a larger number of subjects with different types of RVO. Finally, heterogeneity was observed between the A vs. G (allele), GA vs. GG, GA+AA vs. GG genetic models, which could have biased our analysis. However, no heterogeneity was observed in the subgroup analysis of Caucasians (all I^2^ \< 50%, *P*~H~ \> 0.1). Similarly, we observed no heterogeneity between the BRVO/CRVO subgroups, with the exception of the BRVO subgroup under the GA+AA vs. GG models. Thus, ethnicity and disease type may have contributed to the observed heterogeneity. Our meta-analysis indicates that the G/A genotype of *Factor V* G1691A is associated with an increased risk of RVO, particularly CRVO, in Caucasians.

MATERIALS AND METHODS {#s4}
=====================

Database retrieval and article screening {#s4_1}
----------------------------------------

Using the guidelines of the "Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)" \[[@R56]\], we retrieved articles published before July 27, 2017 from the PubMed, Embase, and WOS databases. Search terms for PubMed included the following: ((((((((((Retinal Vein Occlusion\[MeSH Terms\]) OR occlusion, retinal vein) OR occlusions, retinal vein) OR retinal vein thrombosis) OR retinal vein thromboses) OR thromboses, retinal vein) OR vein thromboses, retinal) OR vein thrombosis, retinal) OR thrombosis, retinal vein)) AND (((((((((*Factor V* \[Other Term\]) OR Proaccelerin) OR AC Globulin) OR Coagulation *Factor V*) OR *Factor V*, Coagulation) OR Factor Pi) OR Blood Coagulation *Factor V*) OR FV Leiden) OR *Factor V* G1691A). We excluded duplicate articles, and then screened and removed ineligible articles using the following exclusion criteria: (1) review article or editorial, (2) case or trial report, (3) meeting abstract or poster, (4) meta-analysis, (5) cell- or animal-based study, (6) unrelated disease, gene, or SNP (7) departure from HWE, and (8) lack of available genotype data.

Data extraction and NOS assessment {#s4_2}
----------------------------------

Three authors independently extracted data from eligible articles including the name of the first author, publication year, country, ethnicity of the study population, genotype frequencies, disease type, genotyping assay, study number, sample size of case/control populations, and source of controls. We assessed the methodological quality of eligible studies using the NOS system (<http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp>).

Statistical analysis {#s4_3}
--------------------

Mantel-Haenszel statistical analysis under fixed- or random-effect models was performed with the Stata/SE 12.0 software (StataCorp, USA). A fixed-effect model was utilized where Cochran's Q statistic (*P*~H~) \> 0.1 or I^2^ \< 50 %. ORs, 95% CIs, and *P*~A~ values were calculated in allele (A vs. G), homozygote (AA vs. GG), heterozygote (GA vs. GG), dominant (GA+AA vs. GG), recessive (AA vs. GG+GA), and carrier (A vs. G) models. Subgroup analysis was performed according to ethnicity, source of controls (PB/HB), and disease type (BRVO/CRVO) under all genetic models. Publication bias was evaluated using Begg's and Egger's tests and sensitivity analysis was performed.

SUPPLEMENTARY MATERIALS FIGURES {#s5}
===============================
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